Exscientia has announced the integration of AI and ML services from Amazon Web Services (AWS) for its drug discovery platform. The collaboration is aimed at producing higher-quality, precision-designed potential therapies.
Exscientia's drug discovery platform incorporates features such as AI models for generating new drug designs and compatibility with AWS' scalable and flexible resources. These attributes allow it to produce drug candidates intended to target individual diseases and patients securely and efficiently specifically.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.